Quantitative analysis of conjunctival goblet cells after chronic application of topical drops

Abstract

Our study illustrates that, in this animal model, once-daily dosing of latanoprost with 0.02% BAK resulted in goblet cell loss compared with dosing with either travoprost with sofZia or preservative-free artificial tears.

Polyoxyethylene Hydrogenated Castor Oil Modulates Benzalkonium Chloride Toxicity: Comparison of Acute Corneal Barrier Dysfunction Induced by Travoprost Z and Travoprost

“…Several comparative studies of ocular surface changes induced by prostaglandin analogs have shown that travoprost Z causes significantly less corneal and conjunctival toxicity as compared to the latanoprost ophthalmic solution that contains 0.02% BAC. [21][22][23][24] In these reports, however, comparisons of travoprost Z with travoprost were not performed. Therefore, we decided to evaluate the corneal toxicity of travoprost Z and travoprost using a newly developed electrophysiological method.…”

Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy

“…28 BAK induces cytotoxic effects leading to apoptosis in conjunctival cell culture, 29,30 and several studies have demonstrated detrimental effects on both conjunctival and corneal cells in rabbit models. [9][10][11] This potential interaction between BAK and OSD is clinically relevant, as a recent study estimated that approximately 60% of glaucoma patients have symptoms of OSD. 4 There may be a potential benefit derived from reducing or eliminating BAK exposure in this population.…”

The Effects of Polyquad-Preserved Travoprost, Benzalkonium Chloride-Preserved Latanoprost, Purite-Preserved Brimonidine and Preservative-Free Tafluprost on Ocular Surface: A Rabbit Ocular Surface Study

“…Kahook ve ark., BAK-latanoprost, Sofzia-travoprost ve prezervan içermeyen suni gözyaşı damlalarının tavşan gözlerine 30 gün boyunca günde bir kez damlatılması sonucu BAK-latanoprost grubunda gözlenen goblet hücre sayısındaki azalmayı diğer iki gruba göre anlamlı bulmuşlardır. 24 BAK konsantrasyonu arttıkça goblet hücre sayısında azalma daha da belirginleşmektedir. 25 BAK içeren antiglokomatöz ajanların glokom gibi kronik bir hastalıkta uzun süreli kullanılması durumunda konjonktivadaki goblet hücre sayısında azalmaya ve buna bağlı oküler yüzey semptomlarına neden olacağı aşikâr-dır.…”